Thousand Oaks Biologics Showcases Innovations in ADC at CPHI Frankfurt
Thousand Oaks Biologics is excited to announce its participation in the highly anticipated CPHI Frankfurt event. This international exhibition, taking place in a major city, serves as a prime platform for companies in the biopharmaceutical space to connect and showcase their innovative solutions.
Global Engagement and Presence
At Booth 4.1H54 in the Bioproduction Zone, Thousand Oaks Biologics will be welcoming visitors from all over the world. The company aims to emphasize its integrated service platform, which is greatly enhanced by its industrial media supplies and cutting-edge AI technologies. This initiative reinforces Thousand Oaks Biologics' commitment as a vital partner within the global biopharmaceutical ecosystem.
Innovation in ADC Technology
Antibody-drug conjugates (ADCs) represent a pivotal advancement in the realm of drug globalisation, particularly in China. With its end-to-end contract development and manufacturing organization (CRDMO) model, Thousand Oaks Biologics is equipped to confront significant challenges in the industry, such as improving efficiency in research and development (R&D), managing scale-up costs, and mitigating regulatory risks.
Robust Supply Chain and Quality Management
The strength of Thousand Oaks Biologics lies in its ability to provide a self-sufficient supply of essential raw materials and enforce stringent quality controls throughout the production process. This capability has established the company as a sought-after partner, having aided over 500 biopharmaceutical firms in expediting their drug development programs.
Core Technologies and Service Offerings
Industrial Media Supply System
Through its innovative serum-free media technology, Thousand Oaks Biologics has created a reliable supply chain for critical components. The company’s intelligent manufacturing framework facilitates smooth transitions from laboratory-scale production to larger commercial quantities. Furthermore, its partnership with local entities and bio-science organizations strengthens its international distribution network, fostering a cost-effective and vertically-integrated infrastructure.
Integrated ADC CMC Technology Platform
The advanced platform for antibody-drug conjugate (ADC) chemistry, manufacturing, and controls (CMC) integrates AI-driven processes to order production streams. This setup significantly minimizes the time and complexity involved in drug development by co-locating various stages of production, from naked antibodies to ADC products, all within a single facility. The Shanghai production site bears the hallmarks of excellence as it has successfully passed regulatory audits and houses extensive production capabilities.
Enhancing Early-Stage R&D
Thousand Oaks Biologics' Ginspire program addresses common obstacles in the development of intricate molecules. It facilitates early-stage R&D services, enabling selections from candidate screening to Investigational New Drug (IND) submissions. This integrated approach simplifies the process, covering everything from molecule design to formulation and pharmacological studies.
Global Strategic Aspirations
The company’s international strategy includes introducing an ADC Early-Stage Support Program while collaborating with European partners to create shared value. By evolving from a simple service provider to a vital strategic ally, Thousand Oaks Biologics aims to support global biopharmaceutical clients at every stage of drug development.
Commitment to the Biopharmaceutical Landscape
Chairman Dr. Luo Shun articulates the necessity for companies in the biopharmaceutical sector to have partners that provide holistic support from the inception of concepts to patient reach. Thousand Oaks Biologics, with its comprehensive CRDMO model and compliance with international standards, stands ready to conquer prevalent industry challenges, ensuring that innovative biologics are accessible to patients everywhere.
Frequently Asked Questions
What does ADC stand for, and why is it important?
ADC stands for Antibody-Drug Conjugate. It is significant because it enhances the delivery of targeted therapies in cancer treatments, improving efficacy while minimizing side effects.
Where can visitors meet the Thousand Oaks Biologics team?
Visitors can connect with the Thousand Oaks Biologics team at Booth 4.1H54 during the CPHI Frankfurt event.
What technologies support Thousand Oaks' offerings?
Their offering is supported by AI-driven technologies, innovative serum-free media production, and a robust CRDMO model that encourages efficiency and quality.
How does Thousand Oaks enhance early-stage drug development?
By providing comprehensive services from candidate selection through to IND submission, Thousand Oaks creates an efficient early-stage continuum for drug development.
What is the company's vision for global partnerships?
The company's vision is to evolve into strategic allies by establishing collaborations across Europe that facilitate co-creation models, addressing the needs of biopharmaceutical clients in a comprehensive manner.
